MYTHY vs. NVO

Last updated Jun 13, 2026

MYTHY (Mytilineos Holdings SA ADR) and NVO (Novo Nordisk A/S) are both stocks. MYTHY operates in Conglomerates (Industrials), while NVO operates in Drug Manufacturers - General (Healthcare).

Performance

MYTHY vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Mytilineos Holdings SA ADR (MYTHY) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

MYTHY

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

NVO

• 1D: -0.18%
• 1M: -4.19%
• YTD: -10.74%
• 6M: -9.50%
• 1Y: -42.47%
• 3Y*: -15.59%
• 5Y*: 2.92%
• 10Y*: 7.56%

*Multi-year figures are annualized to reflect compound growth (CAGR)

MYTHY vs. NVO - Yearly Performance Comparison

	2026 (YTD)
MYTHY Mytilineos Holdings SA ADR	0.00%
NVO Novo Nordisk A/S	4.79%

Fundamentals

Market Cap MYTHY : $8.32B NVO : $195.21B
EPS MYTHY : €2.95 NVO : DKK 27.42
PE Ratio MYTHY : 17.11 NVO : 10.34
PS Ratio MYTHY : 1.38 NVO : 3.85
Total Revenue (TTM) MYTHY : €5.21B NVO : DKK 327.80B
Gross Profit (TTM) MYTHY : €667.88M NVO : DKK 268.30B
EBITDA (TTM) MYTHY : €692.66M NVO : DKK 181.54B

Return for Risk

MYTHY vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MYTHY

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

NVO

NVO Risk / Return Rank: 12
NVO Sharpe Ratio Rank: 9
NVO Sortino Ratio Rank: 12
NVO Omega Ratio Rank: 10
NVO Calmar Ratio Rank: 12
NVO Martin Ratio Rank: 16

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MYTHY vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Mytilineos Holdings SA ADR (MYTHY) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	MYTHY	NVO	Difference
Sharpe ratio: Return per unit of total volatility	—	-0.84	—
Sortino ratio: Return per unit of downside risk	—	-1.05	—
Omega ratio: Gain probability vs. loss probability	—	0.85	—
Calmar ratio: Return relative to maximum drawdown	—	-0.80	—
Martin ratio: Return relative to average drawdown	—	-1.18	—

Drawdowns

MYTHY vs. NVO - Drawdown Comparison

The maximum MYTHY drawdown since its inception was 0.00%, smaller than the maximum NVO drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for MYTHY and NVO.

Drawdown Indicators

	MYTHY	NVO	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-74.70%	+74.70%
Max Drawdown (1Y) Largest decline over 1 year	—	-54.34%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-74.70%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-74.70%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-74.70%	—
Current Drawdown Current decline from peak	0.00%	-68.11%	+68.11%
Average Drawdown Average peak-to-trough decline	0.00%	-17.79%	+17.79%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	37.62%	—

Volatility

Volatility by Period

	MYTHY	NVO	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	10.68%	—
Volatility (6M) Calculated over the trailing 6-month period	—	38.04%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	51.88%	-51.88%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	38.33%	-38.33%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	32.56%	-32.56%

Dividends

MYTHY vs. NVO - Dividend Comparison

MYTHY has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 4.11%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
MYTHY Mytilineos Holdings SA ADR	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVO Novo Nordisk A/S	4.11%	3.31%	1.68%	1.00%	1.20%	1.35%	1.87%	2.14%	1.45%	1.52%	2.87%	0.92%

Financials

MYTHY vs. NVO - Profitability Comparison

The chart below illustrates the profitability comparison between Mytilineos Holdings SA ADR and Novo Nordisk A/S over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

MYTHY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Mytilineos Holdings SA ADR reported a gross profit of 180.41M and revenue of 1.80B. Therefore, the gross margin over that period was 10.0%.

NVO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.

MYTHY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Mytilineos Holdings SA ADR reported an operating income of 142.56M and revenue of 1.80B, resulting in an operating margin of 7.9%.

NVO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.

MYTHY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Mytilineos Holdings SA ADR reported a net income of 126.88M and revenue of 1.80B, resulting in a net margin of 7.0%.

NVO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.